Worried about choosing the right HPV vaccine supplier in India? With so many manufacturers out there, finding a trustworthy one can feel overwhelming—especially when health and reliability are on the line. Selecting the best factory isn’t just about price; quality and safety matter most. Partnering with leading manufacturers means peace of mind, secure supply, and trusted results for your healthcare needs. Curious to see which companies stand out?

Read on to discover India’s top HPV vaccine producers and find your perfect match!

Related Video

Serum Institute Of India – CERVAVAC – Quadrivalent Human Papilloma …

Product Details:
CERVAVAC® is a quadrivalent Human Papillomavirus (HPV) vaccine (recombinant) developed for the prevention of cervical, vulvar, vaginal, and anal cancers, as well as genital warts caused by HPV types 6, 11, 16, and 18. It is supplied as a suspension for injection in single or two-dose vials, intended for use in individuals aged 9-26 years.

Technical Parameters:
– Each 0.5 ml dose contains: HPV 6 L1 protein ≤ 20 mcg, HPV 11 L1 protein ≥ 40
– Produced from Hansenula polymorpha strain
– Pharmaceutical form: Suspension for injection; administered intramuscularly
– Available in 1 dose (0.5 ml) and 2 dose (1.0 ml) vials

Application Scenarios:
– Prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types
– Prevention of anal cancer in boys/men aged 9-26 due to HPV types 16 and 18
– Prevention of genital warts (condyloma acuminata) in both sexes aged 9-26

Pros:
– Protects against four major HPV serotypes (6, 11, 16, 18), covering both cancer
– Simple administration: intramuscular injection, pre-prepared, requires no
– Flexible dosing schedules suited for different age groups (2 doses for 9-14

Cons:
– Safety and efficacy not established for children below 9 years of age
– Vaccine must not be administered intravascularly, subcutaneously, or
– Need for a booster dose is currently not established

Serum Institute Launches India’s First HPV Vaccine

Product Details:
CERVAVAC is India’s first indigenously developed HPV vaccine launched by Serum Institute of India (SII) to prevent cervical cancer. It is intended for use as a preventive measure against human papillomavirus (HPV) infection, which is a major cause of cervical and other cancers.

Technical Parameters:
– Indigenously developed HPV (human papillomavirus) vaccine
– Shown to be nearly 100% effective in preventing cervical cancers caused by
– Most effective if administered to girls aged 9–14 years before sexual exposure
– Developed after 6–7 years of research and clinical development

Application Scenarios:
– Routine vaccination of girls aged 9–14 years to prevent cervical cancer
– Prevention of other HPV-related cancers including genital warts, anal, vulval,
– Public health immunization campaigns in India

Pros:
– First indigenously manufactured HPV vaccine in India, increasing domestic
– Highly effective (nearly 100%) in preventing cervical cancers when administered
– Protects against multiple HPV-related diseases, including certain other cancers
– Supports national cervical cancer prevention efforts, potentially at lower cost

Cons:
– Most effective only when administered before sexual exposure, limiting benefit
– No specific details on side-effect profile or long-term effectiveness beyond

Serum Institute of India launches first made-in-India HPV vaccine for …

Product Details:
The Serum Institute of India has launched the first made-in-India HPV vaccine for the prevention of cervical cancer.

Application Scenarios:
– Prevention of cervical cancer in women
– Vaccination programs targeting human papillomavirus (HPV)

Pros:
– First indigenously developed HPV vaccine in India
– Potentially increases accessibility and affordability for HPV vaccination
– Supports large-scale cervical cancer prevention efforts in India

Vaccine – Cervavac

Product Details:
CERVAVAC® is India’s first domestically-developed quadrivalent HPV vaccine, created by Serum Institute of India (SII) in collaboration with the Department of Biotechnology. It is designed to prevent cervical cancer by targeting four HPV types (6, 11, 16, and 18). The vaccine has received approval from the Drugs Controller General of India (DCGI).

Technical Parameters:
– Quadrivalent vaccine targeting HPV types 6, 11, 16, and 18.
– Each 0.5 ml dose contains: HPV 6 L1 protein ≥ 20 mcg, HPV 11 L1 protein ≥ 40
– Contains Aluminum (Al+++) ≤ 1.25 mg per dose.
– Dosage varies by age group: 2-dose schedule (0 and 6 months) for ages 9–14;

Application Scenarios:
– Routine immunization of girls and young women aged 9–26 years for prevention of
– Public health vaccination campaigns to reduce incidence of cervical cancer in

Pros:
– First domestically-produced HPV vaccine in India, supporting local healthcare
– Targets four high-risk HPV strains most commonly associated with cervical
– Approved by DCGI, ensuring regulatory compliance.
– Developed collaboratively by reputable organizations (SII and DBT).

Cons:
– Application confined to ages 9–26, not indicated for older adult populations.
– Requires multiple doses over several months for full efficacy.

Millions to benefit from Indian-made cervical cancer vaccine – GAVI

Product Details:
CERAVANAC qHPV is an indigenously-developed human papillomavirus (HPV) vaccine launched by the Serum Institute of India, designed to provide an affordable option for cervical cancer prevention.

Technical Parameters:
– Two-dose schedule for girls aged 9 to 14 years
– Three-dose schedule for girls and women aged 15 to 26 years
– Priced at INR 200 (US$ 2.44) to INR 400 (US$ 4.88) per dose
– Production capacity of around 200 million doses in two years

Application Scenarios:
– Mass vaccination campaigns targeting girls and women to prevent cervical cancer
– Integration into national immunisation programmes in India
– Potential future global distribution and use in low- and middle-income countries

Pros:
– Significantly lower cost compared to other HPV vaccines on the market
– Increases accessibility for poorer populations
– Helps address a major health burden (India bears a fifth of global cervical
– Potential to save lives if included in national immunisation programmes

Cons:
– Vaccine availability dependent on government inclusion in immunisation
– Initial rollout limited to India before global expansion

HPV Vaccination in India : New Progress and the way forward

Product Details:
Cervavac is India’s first indigenously manufactured quadrivalent human papillomavirus (HPV) vaccine, targeting HPV types 6, 11, 16, and 18. It is designed to be more affordable and accessible in India and was launched in September 2022, available in the market since January 2023.

Technical Parameters:
– Quadrivalent vaccine targeting HPV types 6, 11, 16, and 18
– Administered intramuscularly in the deltoid region
– Two-dose schedule for ages 9-14 (0 & 6 months), three-dose schedule for ages
– Safety profile supported by over 15 years of monitoring; based on virus-like

Application Scenarios:
– Prevention of cervical cancer and other HPV-related anogenital cancers in
– Mass immunization campaigns among girls aged 9-14 in schools or public health
– Catch-up vaccination for individuals aged 15-26
– Immunization of secondary targets such as boys and immunocompromised

Pros:
– Indigenous production makes the vaccine more affordable and accessible in India
– Effective prevention against HPV types responsible for 80-85% of cervical
– Safe and well-tolerated with minor, transient side effects
– Enables large-scale vaccination efforts due to cost and supply advantages

Cons:
– Does not treat existing HPV infections or related diseases
– Does not cover all cancer-causing HPV types (limited to types 6, 11, 16, 18)
– Efficacy of single-dose schedule for Cervavac not yet established
– Does not eliminate the need for regular cervical cancer screening

Serum Institute Of India – News

Product Details:
CERVAVAC is India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV), launched by Serum Institute of India in partnership with the Department of Biotechnology (DBT), Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation. It aims to protect against HPV infection which is a leading cause of cervical cancer.

Technical Parameters:
– Quadrivalent Human Papillomavirus vaccine (qHPV)
– Developed indigenously in India
– Protects against multiple strains of HPV

Application Scenarios:
– Prevention of cervical cancer in women
– Routine immunization programs targeting adolescent girls
– Public health campaigns during Cervical Cancer Awareness Month

Pros:
– First made-in-India qHPV vaccine, increasing accessibility and affordability in
– Supports national health programs such as cervical cancer prevention
– Public-private partnership enhances credibility and distribution potential

SII launches India’s first indigenously made cervical cancer vaccine …

Product Details:
India’s first indigenously made quadrivalent human papillomavirus (HPV) vaccine for preventing cervical cancer, developed and launched by Serum Institute of India (SII).

Technical Parameters:
– Quadrivalent HPV vaccine (targets HPV types 6, 11, 16, 18)
– Developed using indigenous technology
– Aims to be affordable, with a significantly lower cost compared to imported

Application Scenarios:
– Vaccination for adolescent girls to prevent cervical cancer
– Immunization programs run by government or healthcare organizations in India
– Preventive healthcare in schools and clinics targeting HPV-related diseases

Pros:
– First indigenously developed HPV vaccine in India, promoting self-sufficiency
– More affordable than imported HPV vaccines
– Enables broader access and aids national cervical cancer prevention programs

Cons:
– Limited data provided on large-scale efficacy and long-term safety compared to
– May face initial hesitancy or acceptance barriers due to being a new launch in

Can The Cervavac Vaccine for Cervical Cancer Be a Gamechanger?

Product Details:
Cervavac is India’s first quadrivalent human papillomavirus vaccine (qHPV) for the prevention of cervical cancer, developed and manufactured by Serum Institute of India (SII).

Technical Parameters:
– Quadrivalent HPV vaccine (qHPV)
– Demonstrated antibody response nearly 1,000 times higher than baseline against
– Completed Phase 2 and Phase 3 clinical trials
– Designed for multiple doses and various age groups

Application Scenarios:
– Vaccinating girls aged 10 or 11 to prevent cervical cancer
– Mass immunization programs for adolescent females
– Use as a preventive measure in populations at risk of HPV infection

Pros:
– First Indian-origin HPV vaccine, improving local accessibility
– Affordable compared to imported alternatives
– Strong antibody response across age groups and doses
– Potential to reduce high incidence and mortality of cervical cancer in Indian

Cons:
– Barriers to accessibility have existed historically (prior to this vaccine’s
– Effectiveness depends on timely vaccination (ideally before HPV exposure)

MSD rolls out India’s first gender-neutral Human Papillomavirus vaccine

Product Details:
MSD has launched India’s first gender-neutral Human Papillomavirus (HPV) vaccine, targeting prevention of HPV-related diseases for all genders.

Application Scenarios:
– Vaccination programs for both males and females
– Prevention of HPV-related cancers and diseases in the general population
– Public health immunization drives in schools and communities

Pros:
– First gender-neutral HPV vaccine available in India
– Offers protection to both men and women against HPV
– Potential to reduce incidence of multiple HPV-related cancers

Cons:
– Technical specifications and side effect profiles are not detailed
– Uptake may be limited by public awareness or cost

Comparison Table

Company	Product Details	Pros	Cons	Website
Serum Institute Of India – CERVAVAC – Quadrivalent Human Papilloma …	CERVAVAC® is a quadrivalent Human Papillomavirus (HPV) vaccine (recombinant)	Protects against four major HPV serotypes (6, 11, 16, 18), covering both cancer	Safety and efficacy not established for children below 9 years of age Vaccine	www.seruminstitute.com
Serum Institute Launches India’s First HPV Vaccine	CERVAVAC is India’s first indigenously developed HPV vaccine launched by Serum	First indigenously manufactured HPV vaccine in India, increasing domestic	Most effective only when administered before sexual exposure, limiting benefit	www.medindia.net
Serum Institute of India launches first made-in-India HPV vaccine for …	The Serum Institute of India has launched the first made-in-India HPV vaccine	First indigenously developed HPV vaccine in India Potentially increases		health.economictimes.indiatimes.com
Vaccine – Cervavac	CERVAVAC® is India’s first domestically-developed quadrivalent HPV vaccine,	First domestically-produced HPV vaccine in India, supporting local healthcare	Application confined to ages 9–26, not indicated for older adult populations	cervavac.com
Millions to benefit from Indian-made cervical cancer vaccine – GAVI	CERAVANAC qHPV is an indigenously-developed human papillomavirus (HPV) vaccine	Significantly lower cost compared to other HPV vaccines on the market Increases	Vaccine availability dependent on government inclusion in immunisation	www.gavi.org
HPV Vaccination in India : New Progress and the way forward	Cervavac is India’s first indigenously manufactured quadrivalent human	Indigenous production makes the vaccine more affordable and accessible in	Does not treat existing HPV infections or related diseases Does not cover all	www.rgcirc.org
Serum Institute Of India – News	CERVAVAC is India’s first indigenously developed Quadrivalent Human	First made-in-India qHPV vaccine, increasing accessibility and affordability in		www.seruminstitute.com
SII launches India’s first indigenously made cervical cancer vaccine …	India’s first indigenously made quadrivalent human papillomavirus (HPV) vaccine	First indigenously developed HPV vaccine in India, promoting self-sufficiency Mo	Limited data provided on large-scale efficacy and long-term safety compared to	www.financialexpress.com
Can The Cervavac Vaccine for Cervical Cancer Be a Gamechanger?	Cervavac is India’s first quadrivalent human papillomavirus vaccine (qHPV) for	First Indian-origin HPV vaccine, improving local accessibility Affordable	Barriers to accessibility have existed historically (prior to this vaccine’s	thebetterindia.com
MSD rolls out India’s first gender-neutral Human Papillomavirus vaccine	MSD has launched India’s first gender-neutral Human Papillomavirus (HPV)	First gender-neutral HPV vaccine available in India Offers protection to both	Technical specifications and side effect profiles are not detailed Uptake may	m.timesofindia.com

Frequently Asked Questions (FAQs)

How can I identify reputable HPV vaccine manufacturers in India?
Start by looking for manufacturers certified by regulatory authorities like WHO, DCGI, and GMP. Check their company reputation, years in operation, quality certifications, and their portfolio. Conducting online research and requesting references from healthcare professionals can also help.

What factors should I consider when choosing an HPV vaccine supplier?
Focus on quality certifications, production capacity, pricing, reliability of supply, and after-sales support. It’s also wise to review terms related to delivery timelines and cold chain management for vaccines.

How do I verify the authenticity of an HPV vaccine manufacturer?
Request documentation like registration certificates, compliance records, and details of regulatory inspections. You can also visit their facilities if possible, and seek feedback from existing customers.

Are there specific HPV vaccines manufactured in India that are WHO prequalified?
Yes, some Indian manufacturers produce WHO-prequalified HPV vaccines. Check the WHO’s prequalified vaccines list or ask the manufacturer directly for proof of WHO accreditation.

Can I request samples or technical data before making a bulk purchase?
Most reputable manufacturers will provide product samples, certificates of analysis, and detailed technical data sheets upon request. This helps ensure the vaccine meets your quality and safety requirements before committing to a large order.